普伐他汀对晚期胃癌患者生存率的影响。
Effect of pravastatin on the survival of patients with advanced gastric cancer.
作者信息
Bujanda Luis, Rodríguez-González Araceli, Sarasqueta Cristina, Eizaguirre Emma, Hijona Elizabeth, Marín José J G, Perugorria María J, Banales Jesús M, Cosme Angel
机构信息
Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain.
National Institute for The Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
出版信息
Oncotarget. 2016 Jan 26;7(4):4379-84. doi: 10.18632/oncotarget.6777.
OBJECTIVES
A fluoropyrimidine plus cisplatin combined with surgery is standard first-line treatment for advanced gastric cancer. We evaluated the effect of pravastatin on overall survival in patients with advanced gastric cancer in a prospective cohort study.
METHODS
At the time of surgery, we assigned 60 patients with advanced gastric cancer (stage III or IV) to receive standard first-line treatment (control group) or standard first-line treatment plus pravastatin at a dose of 40 mg once daily (pravastatin group). The minimum follow-up period was 4 years and the maximum of 6 years.
RESULTS
The mean of age was 66 years and the TNM stage was III and IV in 65% and 35% of patients, respectively. There was no significant difference between the two groups (control vs pravastatin) in median overall survival (15 vs 14 months; P = 0.8). Predictors of survival were the stage (hazard ratio of death stage IV (III stage as reference): 4.4; 95% CI: 2-9.7; p < 0.05) and older age (hazard ratio of death ≥ 65 years (< 65 years as reference): 2.8; 95% CI: 1.3-6; p < 0.05).
CONCLUSIONS
Pravastatin did not improve outcome in patients with advanced gastric cancer.
目的
氟嘧啶加顺铂联合手术是晚期胃癌的标准一线治疗方案。我们在一项前瞻性队列研究中评估了普伐他汀对晚期胃癌患者总生存期的影响。
方法
在手术时，我们将60例晚期胃癌患者（III期或IV期）分为两组，一组接受标准一线治疗（对照组），另一组接受标准一线治疗加每日一次40毫克的普伐他汀（普伐他汀组）。最短随访期为4年，最长为6年。
结果
患者的平均年龄为66岁，TNM分期为III期和IV期的患者分别占65%和35%。两组（对照组与普伐他汀组）的中位总生存期无显著差异（15个月对14个月；P = 0.8）。生存的预测因素为分期（IV期死亡风险比（以III期为参照）：4.4；95%置信区间：2 - 9.7；p < 0.05）和年龄较大（≥65岁死亡风险比（以<65岁为参照）：2.8；95%置信区间：1.3 - 6；p < 0.05）。
结论
普伐他汀未能改善晚期胃癌患者的预后。
Zotero 插件